Drug intelligence / Profile preview

esketamine + pregabalin

Development stage: Unknown
Lead developer: OMJ Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination of esketamine and pregabalin used for pain management. Esketamine is an NMDA receptor antagonist while pregabalin acts on calcium channels to reduce pain signals. The combination shows synergistic analgesic effects, particularly effective for acute postsurgical pain management with reduced opioid requirements. Clinical studies demonstrate significant reduction in moderate-to-severe pain after spinal surgery and other procedures compared to either drug alone or placebo.

Other names: s-ketamine + pregabalin

Targets

CACNA2D2 (α2δ-2)NMDAR (Glutamate receptor ionotropic, NMDA)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)

Beyond the preview

Go deeper on esketamine + pregabalin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on esketamine + pregabalin.

Explore the full profile